| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8e8f78a48eb4cab18a363ec9dcb5d84 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 |
| filingDate |
2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc187f364d8fcf403710a5833adbe5d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae3d6873a455cac7c257f2e42604ca15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e30feb174ffdca61dbb94e1dc90aeaad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee95a5ea11207edc0463c2d6c0894a1a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7e04a7e66fe0f7e096dca0782574edd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c24905fa71100014dc45da987df1ad55 |
| publicationDate |
2017-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2619216-C1 |
| titleOfInvention |
Method of selecting the immunosuppression regime to children of early age in a remote period after transplantation of the liver |
| abstract |
FIELD: medicine. n SUBSTANCE: one year after transplantation in blood serum, the content of insulin-like growth factor 1 (IGF-1) and soluble CD30 (sCD30) is determined in liver recipients, and the dose of tacrolimus is adjusted to the specific concentration of IGF-1 and sCD30, the daily dose of tacrolimus is determined by formula D=1.3764+0.0081×G-0.0026×C, where D is the daily dose of tacrolimus, mg; G - serum level of IGF-1, ng/ml; C - content of sCD30 in serum, ng/ml. n EFFECT: use of this method allows for effective prevention of complications in young children after liver transplantation for congenital diseases of the hepatobiliary system in the long-term due to individual selection of tacrolimus concentration one year after liver transplantation. n 5 ex |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764742-C1 |
| priorityDate |
2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |